查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1625468

難治性痛風市場規模、佔有率、趨勢、行業分析報告（按治療類型、分銷管道和地區）- 市場預測，2025-2034 年

Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，到2034年全球痛風市場規模預計將達到15.9924億美元。該研究報告對當前市場動態提供了詳細的見解，並對未來市場成長進行了分析。

由於對常規治療沒有反應的嚴重痛風病例數量不斷增加，難治性痛風市場正在穩步擴大。難治性痛風的特徵是儘管接受了標準治療，症狀仍會持續存在，需要先進的治療方法，這是推動市場成長的主要因素。市場分為生物療法和非生物療法，其中生物療法由於其針對性作用和在治療複雜病例方面的高效性而佔據了顯著的市場佔有率。這些治療方法包括單株抗體和酵素抑制劑，越來越受歡迎，刺激了市場需求並促進了市場擴張。

醫療保健專業人員和患者對創新治療方案可用性的認識不斷提高也是推動市場規模的關鍵因素。醫院和專科診所是治療難治性痛風的主要機構，提供先進的治療和專業的護理，在市場成長中發揮關鍵作用。隨著生物製劑的應用日益廣泛和專業設施的普及，該行業預計將顯著增長。

技術的進步、持續的研究和開發以及新藥的批准進一步加強了難治性痛風市場。此外，老年人口的不斷增長，使他們更容易患上嚴重的痛風，這也促使市場需求的增加。旨在改善獲得先進治療機會的有利政府措施和醫療政策也支持了市場擴張。

難治性痛風市場報告重點

根據治療類型，生物製劑由於其廣泛的應用範圍和在症狀管理方面的有效性，在難治性痛風市場中佔據主要市場佔有率。

根據分銷管道，預計預測期內治療嚴重複雜病例的醫院和專科診所將顯著增長。

由於北美擁有先進的醫療基礎設施和高痛風盛行率，因此佔難治性痛風市場的最大佔有率。

由於新興經濟體醫療保健投資的增加以及人們對痛風管理的認識的不斷提高，預計亞太地區將在預測期內出現顯著增長。

目錄

第 1 章簡介

第 2 章執行摘要

第 3 章 研究方法

第 4 章全球難治性痛風市場洞察

  • 市場概況
  • 難治性痛風市場動態
    • 推動因素和機遇
      • 治療難治性痛風的生物製劑需求不斷增加
      • 越來越重視個人化醫療和基因檢測
    • 阻礙因素和課題
      • 醫療費用高昂
  • PESTEL 分析
  • 難治性痛風市場的應用趨勢
  • 價值鏈分析
  • COVID-19 影響分析

第 5 章全球難治性痛風市場（依治療類型劃分）
  • 主要發現
  • 簡介
  • 生物治療
  • 非生物治療

第6章 全球難治性痛風市場依通路劃分

  • 主要發現
  • 簡介
  • 醫院和專科診所
  • 零售藥局
  • 網路藥局

第7章 全球難治性痛風市場（按地區）

  • 主要發現
  • 簡介
    • 難治性痛風市場評估：各地區，2020 年至 2034 年
  • 北美洲
    • 2020 年至 2034 年，北美依治療類型劃分
    • 2020 年至 2034 年，北美依通路劃分
    • 美國
    • 加拿大
  • 歐洲
      2020 年至 2034 年歐洲依治療類型劃分 2020 年至 2034 年歐洲按通路劃分
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲國家
    亞太地區
      亞太地區，依治療類型，2020 年至 2034 年 2020 年至 2034 年亞太地區通路分佈
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲
      中東和非洲：依治療類型，2020 年至 2034 年 2020 年至 2034 年中東和非洲按分銷管道劃分
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲地區
  • 拉丁美洲
    • 拉丁美洲，依治療類型，2020 年至 2034 年
    • 2020 年至 2034 年拉丁美洲依通路劃分
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家

第 8 章 競爭格局

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協定/揭露

第9章 公司簡介

  • Horizon Therapeutics
  • Novartis AG
  • Takeda Pharmaceuticals
  • Grifols, S.A.
  • Ironwood Pharmaceuticals
  • Selecta Biosciences
  • Teijin Pharma
  • Pfizer Inc.
  • Sobi（Swedish Orphan Biovitrum）
  • LG Chem
  • AstraZeneca
  • Mylan N.V.
  • Sanofi
  • GlaxoSmithKline plc（GSK）
  • Ardea Biosciences
Product Code: PM5327

The global refractory gout market size is expected to reach USD 1,599.24 million by 2034, according to a new study by Polaris Market Research. The report "Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Biological and Non-Biological Treatments), Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The refractory gout market is witnessing steady expansion, driven by the increasing prevalence of severe gout cases unresponsive to conventional therapies. Refractory gout, characterized by persistent symptoms despite standard treatment, requires advanced therapeutic approaches, which significantly contribute to market growth. The market is segmented into biological and non-biological treatments, with biological therapies gaining notable market share due to their targeted action and higher efficacy in managing complex cases. These treatments, which include monoclonal antibodies and enzyme inhibitors, are increasingly favored, boosting market demand and fostering market expansion.

The rising awareness among healthcare professionals and patients about the availability of innovative treatment options is another crucial factor driving market size. Hospitals and specialty clinics, as primary treatment providers for refractory gout, play a pivotal role in market growth by offering access to advanced therapies and expert care. This segment is expected to witness significant growth, supported by the increasing adoption of biologics and the availability of specialized facilities.

Technological advancements, ongoing research and development, and the approval of novel drugs are further enhancing the refractory gout market. Additionally, the growing geriatric population, which is more susceptible to severe gout, is contributing to the increasing market demand. Favorable government initiatives and healthcare policies aimed at improving access to advanced treatments also support market expansion.

Refractory Gout Market Report Highlights:

In terms of treatment type, the biological treatment segment holds the significant market share in the refractory gout market due to their broad application and efficacy in managing symptoms.

By distribution channel, the hospitals and specialty clinics segment is expected to witness significant growth over the forecast period, driven by their capacity to handle severe and complex cases.

North America holds the largest share of the refractory gout market, with its advanced healthcare infrastructure and high prevalence of gout.

Asia Pacific is expected to witness significant growth over the forecast period, owing to increasing healthcare investments and rising awareness of gout management in emerging economies.

Polaris Market Research has segmented the refractory gout market report on the basis of treatment type, distribution channel, and region:

By Treatment Type Outlook (Revenue USD Million, 2020-2034)

  • Biologics
  • Pegloticase (Krystexxa)
  • Canakinumab
  • Non-Biologics
  • NSAIDs
  • Corticosteroids
  • Colchicine
  • Uricosurics (e.g., probenecid)

By Distribution Channel Outlook (Revenue USD Million, 2020-2034)

  • Hospitals and Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

By Regional Outlook (Revenue USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Refractory Gout Market Insights

  • 4.1. Refractory Gout Market - Market Snapshot
  • 4.2. Refractory Gout Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Demand for Biologics in Refractory Gout Treatment
      • 4.2.1.2. Surging Focus on Personalized Medicine and Genetic Testing
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Refractory Gout Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Refractory Gout Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
  • 5.3. Biologics
    • 5.3.1. Global Refractory Gout Market, by Biologics, by Region, 2020-2034 (USD Million)
    • 5.3.2. Pegloticase (Krystexxa)
      • 5.3.2.1. Global Refractory Gout Market, by Pegloticase (Krystexxa), by Region, 2020-2034 (USD Million)
    • 5.3.3. Canakinumab
      • 5.3.3.1. Global Refractory Gout Market, by Canakinumab, by Region, 2020-2034 (USD Million)
  • 5.4. Non-Biologics
    • 5.4.1. Global Refractory Gout Market, by Non-Biologics, by Region, 2020-2034 (USD Million)
    • 5.4.2. NSAIDs
      • 5.4.2.1. Global Refractory Gout Market, by NSAIDs, by Region, 2020-2034 (USD Million)
    • 5.4.3. Corticosteroids
      • 5.4.3.1. Global Refractory Gout Market, by Corticosteroids, by Region, 2020-2034 (USD Million)
    • 5.4.4. Colchicine
      • 5.4.4.1. Global Refractory Gout Market, by Colchicine, by Region, 2020-2034 (USD Million)
    • 5.4.5. Uricosurics (e.g., probenecid)
      • 5.4.5.1. Global Refractory Gout Market, by Uricosurics (e.g., probenecid), by Region, 2020-2034 (USD Million)

6. Global Refractory Gout Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 6.3. Hospitals and Specialty Clinics
    • 6.3.1. Global Refractory Gout Market, by Hospitals and Specialty Clinics, by Region, 2020-2034 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Refractory Gout Market, by Retail Pharmacies, by Region, 2020-2034 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Refractory Gout Market, by Online Pharmacies, by Region, 2020-2034 (USD Million)

7. Global Refractory Gout Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Refractory Gout Market Assessment, By Geography, 2020-2034 (USD Million)
  • 7.3. Refractory Gout Market - North America
    • 7.3.1. North America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.3.2. North America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.3.3. Refractory Gout Market - US
      • 7.3.3.1. US: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.3.3.2. US: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.3.4. Refractory Gout Market - Canada
      • 7.3.4.1. Canada: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.3.4.2. Canada: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.4. Refractory Gout Market - Europe
    • 7.4.1. Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.4.2. Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.3. Refractory Gout Market - UK
      • 7.4.3.1. UK: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.3.2. UK: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.4. Refractory Gout Market - France
      • 7.4.4.1. France: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.4.2. France: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.5. Refractory Gout Market - Germany
      • 7.4.5.1. Germany: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.5.2. Germany: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.6. Refractory Gout Market - Italy
      • 7.4.6.1. Italy: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.6.2. Italy: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.7. Refractory Gout Market - Spain
      • 7.4.7.1. Spain: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.7.2. Spain: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.8. Refractory Gout Market - Netherlands
      • 7.4.8.1. Netherlands: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.8.2. Netherlands: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.9. Refractory Gout Market - Russia
      • 7.4.9.1. Russia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.9.2. Russia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.10. Refractory Gout Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.10.2. Rest of Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.5. Refractory Gout Market - Asia Pacific
    • 7.5.1. Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.5.2. Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.3. Refractory Gout Market - China
      • 7.5.3.1. China: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.3.2. China: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.4. Refractory Gout Market - India
      • 7.5.4.1. India: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.4.2. India: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.5. Refractory Gout Market - Malaysia
      • 7.5.5.1. Malaysia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.5.2. Malaysia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.6. Refractory Gout Market - Japan
      • 7.5.6.1. Japan: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.6.2. Japan: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.7. Refractory Gout Market - Indonesia
      • 7.5.7.1. Indonesia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.7.2. Indonesia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.8. Refractory Gout Market - South Korea
      • 7.5.8.1. South Korea: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.8.2. South Korea: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.9. Refractory Gout Market - Australia
      • 7.5.9.1. Australia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.9.2. Australia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.10. Refractory Gout Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.10.2. Rest of Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.6. Refractory Gout Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.6.2. Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.3. Refractory Gout Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.3.2. Saudi Arabia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.4. Refractory Gout Market - UAE
      • 7.6.4.1. UAE: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.4.2. UAE: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.5. Refractory Gout Market - Israel
      • 7.6.5.1. Israel: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.5.2. Israel: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.6. Refractory Gout Market - South Africa
      • 7.6.6.1. South Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.6.2. South Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.7. Refractory Gout Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.7.2. Rest of Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.7. Refractory Gout Market - Latin America
    • 7.7.1. Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.7.2. Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.3. Refractory Gout Market - Mexico
      • 7.7.3.1. Mexico: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.3.2. Mexico: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.4. Refractory Gout Market - Brazil
      • 7.7.4.1. Brazil: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.4.2. Brazil: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.5. Refractory Gout Market - Argentina
      • 7.7.5.1. Argentina: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.5.2. Argentina: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.6. Refractory Gout Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.6.2. Rest of Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Horizon Therapeutics
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Takeda Pharmaceuticals
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Grifols, S.A.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Ironwood Pharmaceuticals
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Selecta Biosciences
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Teijin Pharma
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Pfizer Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Sobi (Swedish Orphan Biovitrum)
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. LG Chem
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. AstraZeneca
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Mylan N.V.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Sanofi
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. GlaxoSmithKline plc (GSK)
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Ardea Biosciences
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development

List of Tables:

Table 1 Global Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 2 Global Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 3 North America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 4 North America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 5 US: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 6 US: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 7 Canada: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 8 Canada: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 9 Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 10 Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 11 UK: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 12 UK: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 13 France: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 14 France: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 15 Germany: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 16 Germany: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 17 Italy: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 18 Italy: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 19 Spain: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 20 Spain: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 21 Netherlands: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 22 Netherlands: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 23 Russia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 24 Russia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 25 Rest of Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 26 Rest of Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 27 Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 28 Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 29 China: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 30 China: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 31 India: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 32 India: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 33 Malaysia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 34 Malaysia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 35 Japan: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 36 Japan: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 37 Indonesia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 38 Indonesia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 39 South Korea: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 40 South Korea: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 41 Australia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 42 Australia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 43 Rest of Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 44 Rest of Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 45 Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 46 Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 47 Saudi Arabia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 48 Saudi Arabia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 49 UAE: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 50 UAE: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 51 Israel: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 52 Israel: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 53 South Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 54 South Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 55 Rest of Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 56 Rest of Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 57 Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 58 Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 59 Mexico: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 60 Mexico: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 61 Brazil: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 62 Brazil: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 63 Argentina: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 64 Argentina: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 65 Rest of Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 66 Rest of Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

List of Figures:

Figure 1. Global Refractory Gout Market, 2020-2034 (USD Million)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Treatment Type

Figure 7. Global Refractory Gout Market, by Treatment Type, 2024 & 2034 (USD Million)

Figure 8. Market by Distribution Channel

Figure 9. Global Refractory Gout Market, by Distribution Channel, 2024 & 2034 (USD Million)